Conexeu Sciences Inc

Founded in late 2022, Conexeu Sciences is advancing regenerative medicine through its patented collagen–based liquid platform. Emerging from over a decade of university research, the Company is developing a human collagen-based liquid scaffold that transitions from liquid to gel at body temperature, forming a thermosensitive scaffold that accelerates organized tissue formation. With patents across the U.S, E.U, Japan, and Australia, and additional filings pending globally, Conexeu’s CXU™ platform offers transformative potential across multi-billion-dollar markets. At the forefront of Conexeu’s portfolio is Ten Minute Tissue™, a collagen-based extracellular matrix (ECM) that remains fluid at room temperature and gels at ~37°C. This unique scaffold promotes cell migration, proliferation, differentiation, and new tissue formation, enabling seamless integration into host tissue. Clinically proven in pre-clinical studies, Ten Minute Tissue™ accelerates healing while reducing inflammation and non-fibrotic scarring. Ten-Minute Tissue™ is an investigational product and has not been cleared or approved by any regulatory authority.